Adherence of Iron Succinylate Therapy in Pregnancy
Adherence of Iron Succinylate Therapy in Pregnancy
According to the World Health Organization (WHO), anemia is the most common disease,
 affecting >1.5 billion people worldwide. Furthermore, iron deficiency anemia (IDA) accounts
 for 50% of cases of anemia. IDA is common during pregnancy and the postpartum period, and can
 lead to serious maternal and fetal complications. Measurement of serum ferritin has the
 highest sensitivity and specificity for diagnosis of IDA unless there is a concurrent
 inflammatory condition. The lower threshold value for hemoglobin (Hb) in pregnant women is
 <11 g/dL during the 1st and 3rd trimesters, and <10.5 g/dL during the 2nd trimester. In
 postpartum period a Hb concentration <10 g/dL indicates clinically significant anemia. Oral
 iron therapy is given as the first-line treatment for IDA.
Measurement of serum ferritin has the highest sensitivity and specificity for diagnosis of
 IDA unless there is a concurrent inflammatory condition. The lower threshold value for
 hemoglobin (Hb) in pregnant women is <11 g/dL during the 1st and 3rd trimesters, and <10.5
 g/dL during the 2nd trimester. In postpartum period a Hb concentration <10 g/dL indicates
 clinically significant anemia.

 Oral iron therapy is given as the first-line treatment for IDA. There are several direct and
 indirect methods to assess adherence to medications, each method has advantages and limits.
 Many studies have shown that pill counting is more accurate than self-reported adherence.We
 will investigate the adherence to iron supplementation in pregnant women by using a
 self-reported adherence questionnaire named SMAQ (Simplified Medication Adherence
 Questionnaire)

 Simplified Medication Adherence Questionnaire (SMAQ) Knobel H; Juega J; Carmona A; Kindelan
 JM; Ruiz I; Gonzalez J; Collazos J; Casado JL; Alonso J; Ocampo A SMAQ is used to assess
 non-adherent patients. The six-item SMAQ has been developed to assess adherence in
 HIV-infected patients, and may be applied in most clinical settings.
Inclusion Criteria:

 -  Pregnancy

 -  Anaemia

 -  Iron treatment before 3 months of pregnancy

 -  Informed Consent

 -  Compliant with study procedures

 Exclusion Criteria:

 -  Iron treatment after 3 months of pregnancy